Advancing Cancer Diagnosis and Treatment: Integrating Molecular Biomarkers and Emerging Technologies
Biomedical Journal,
Год журнала:
2025,
Номер
unknown, С. 100831 - 100831
Опубликована: Янв. 1, 2025
Язык: Английский
Inherently imperfect, inherently evolving – the pursuit of precision through biomarkers
Biomedical Journal,
Год журнала:
2025,
Номер
unknown, С. 100839 - 100839
Опубликована: Фев. 1, 2025
Язык: Английский
Cell-free DNA: plays an essential role in early diagnosis and immunotherapy of pancreatic cancer
Frontiers in Immunology,
Год журнала:
2025,
Номер
16
Опубликована: Март 7, 2025
Pancreatic
cancer
is
renowned
for
its
aggressive
nature
and
dismal
prognosis,
with
the
majority
of
patients
diagnosed
at
an
advanced
stage.
The
prognosis
pancreatic
can
be
improved
by
early
diagnosis
effective
treatment.
Circulating
cell-free
DNA
(cfDNA)
has
emerged
as
a
promising
biomarker
monitoring
cancer.
This
research
presents
review
circulating
essential
role
in
immunotherapy
detection
methods
cfDNA,
potential
diagnostic
biomarker,
latest
progress
cfDNA-based
are
discussed.
findings
suggest
that
cfDNA
plays
vital
personalised
treatment
cancer,
holding
great
promise
improving
patient
outcomes.
Язык: Английский
Plasma Cell-Free DNA Methylation-Based Prognosis in Metastatic Castrate-Resistant Prostate Cancer
Research Square (Research Square),
Год журнала:
2025,
Номер
unknown
Опубликована: Апрель 21, 2025
Molecular
prognostication
in
metastatic
castration
prostate
cancer
(mCRPC)
remains
challenging
due
to
the
lack
of
validated
biomarkers.
This
study
developed
a
plasma
cell-free
DNA
(cfDNA)
methylation-based
prognostic
model
mCRPC.
Targeted
cfDNA
methylation
sequencing
96
patients
different
states
progression
revealed
78
haplotype
blocks
(MHBs)
differentially
methylated
from
organ-confined
mCRPC
states.
Among
these
MHBs,
top
20
MHBs
were
associated
with
overall
survival
and
most
MHB
levels
positively
correlated
predicted
circulating
tumor
(ctDNA)
fraction.
By
integrating
MHB-based
risk
score
currently
available
clinical
variables
ctDNA
fraction
nomogram
was
which
showed
high
predictive
performance
for
(AUC
=
0.99
6
months,
AUC
0.90
1
year,
0.87
2
years).
These
findings
demonstrate
potential
as
molecular
biology-driven
biomarker
prognosis.
Язык: Английский
Epigenetic modulation by oncolytic viruses: Implications for cancer therapeutic efficacy
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer,
Год журнала:
2025,
Номер
unknown, С. 189270 - 189270
Опубликована: Янв. 1, 2025
Язык: Английский
Liquid biopsy for early cancer detection: technological revolutions and clinical dilemma
Expert Review of Molecular Diagnostics,
Год журнала:
2024,
Номер
unknown, С. 1 - 19
Опубликована: Окт. 3, 2024
Liquid
biopsy
is
an
innovative
advancement
in
oncology,
offering
a
noninvasive
method
for
early
cancer
detection
and
monitoring
by
analyzing
circulating
tumor
cells,
DNA,
RNA,
other
biomarkers
bodily
fluids.
This
technique
has
the
potential
to
revolutionize
precision
oncology
providing
real-time
analysis
of
dynamics,
enabling
detection,
treatment
responses,
tailoring
personalized
therapies
based
on
molecular
profiles
individual
patients.
Язык: Английский